Evolus: Strategic Developments and FDA Approvals Drive Buy Rating With Promising Growth Projections

TipRanksFeb 17 03:15 ET · Ratings

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?

Zacks Feb 14 07:55 ET

An Excellent Week for Evolus, Inc.'s (NASDAQ:EOLS) Institutional Owners Who Own 70% as One-year Returns Inch Higher

Simply Wall StFeb 14 07:47 ET

Investors Appear Satisfied With Evolus, Inc.'s (NASDAQ:EOLS) Prospects As Shares Rocket 59%

Simply Wall StFeb 14 07:44 ET

Breaking Down Evolus: 4 Analysts Share Their Views

BenzingaFeb 14 07:00 ET

Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating

Moomoo NewsFeb 14 01:32 ET · Ratings